Shankar Musunuri,Sandeep Jain,Rasappa Arumugham,Arun K. Upadhyay,Matthew Nudell,Gopalam Somasekhar
申请号：
US15946709
公开号：
US20180333414A1
申请日:
2018.04.05
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist； (ii) a corticosteroid； (iii) a lymphocyte function-associated antigen antagonist； (iv) a non-steroidal anti-inflammatory drug (NSAID)； (v) a sodium channel blocker； and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid. The present invention also provides a method for using such composition to treat an eye disorder such as a dry eye syndrome； ocular graft-versus-host-disease； ocular rosacea； allergic conjunctivitis； autoimmune ocular surface disease； thygeson's superficial punctuate keratopathy； herpes zoster keratitis； Stevens-Johnson syndrome； keratitis； conjunctivitis； blepharitis； blepharochalasis； conjunctivochalasis； blepharoconjunctivitis； blepharokeratoconjunctivitis； post-operative inflammation or pain from ocular surgery； scleritis； episcleritis； anterior uveitis； iritis； cyclitis； ocular surface vascular disorder； ulcerative keratitis； photokeratitis； dacryocystitis； eyelid disorder； congenital alacrima； xerophthalmia； dacryoadenitis； vernal keratoconjunctivitis； pinguecula； and/or ocular surface disorder induced by chemical burns, thermal burns, or physical insult to the ocular surface.
